Swiss biotechnology group Serono is gearing up its $10bn (£5.5bn) acquisition drive, which could include a tilt at pharmaceutical giant Shire.
"Management has a clear, renewed sense of urgency to do a deal," said ABN Amro fund manager Arnoud Diemers, who recently spoke with management. Investors have been pressing the company to deliver on the pledge it made in April to hit the acquisition trail after it failed to sell itself.
Let's hope they dont end up tilting at the wrong target.
More here in The Independent.
No comments:
Post a Comment